

Global Generic Drugs Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

https://marketpublishers.com/r/GF8643CE028AEN.html

Date: April 2024

Pages: 210

Price: US\$ 4,250.00 (Single User License)

ID: GF8643CE028AEN

Abstracts

Summary

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

According to APO Research, The global Generic Drugs market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Generic Drugs is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through



2030.

The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Generic Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Generic Drugs, also provides the value of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and subsegments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Generic Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Generic Drugs segment by Company

Teva

Novartis - Sandoz

Mylan



Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech



Kotra Pharma			
HOE Pharmaceutical			
Y.S.P. Industries			
Generic Drugs segment by Type			
Prescription			
Non-Prescription Drugs			
Generic Drugs segment by Application			
Hospital			
Clinic			
Others			
Generic Drugs segment by Region			
North America			
U.S.			
Canada			
Europe			
Germany			
France			
U.K.			



	Italy	
	Russia	
Asia-Pa	acific	
	China	
	Japan	
	South Korea	
	India	
	Australia	
	China Taiwan	
	Indonesia	
	Thailand	
	Malaysia	
Latin A	merica	
	Mexico	
	Brazil	
	Argentina	
Middle East & Africa		
	Turkey	
	Saudi Arabia	



UAE

Study Objectives

- 1. To analyze and research the global Generic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
- 2. To present the Generic Drugs key companies, revenue, market share, and recent developments.
- 3. To split the Generic Drugs breakdown data by regions, type, companies, and application.
- 4. To analyze the global and key regions Generic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
- 5. To identify Generic Drugs significant trends, drivers, influence factors in global and regions.
- 6. To analyze Generic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

- 1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- 2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
- 3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape



section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

- 4. This report stays updated with novel technology integration, features, and the latest developments in the market.
- 5. This report helps stakeholders to gain insights into which regions to target globally.
- 6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
- 7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Drugs industry.

Chapter 3: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Generic Drugs in country level. It provides sigmate data by



type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.



Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Global Generic Drugs Market Size, 2019 VS 2023 VS 2030
- 1.3 Global Generic Drugs Market Size (2019-2030)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 GENERIC DRUGS MARKET DYNAMICS

- 2.1 Generic Drugs Industry Trends
- 2.2 Generic Drugs Industry Drivers
- 2.3 Generic Drugs Industry Opportunities and Challenges
- 2.4 Generic Drugs Industry Restraints

3 GENERIC DRUGS MARKET BY COMPANY

- 3.1 Global Generic Drugs Company Revenue Ranking in 2023
- 3.2 Global Generic Drugs Revenue by Company (2019-2024)
- 3.3 Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024
- 3.4 Global Generic Drugs Company Manufacturing Base & Headquarters
- 3.5 Global Generic Drugs Company, Product Type & Application
- 3.6 Global Generic Drugs Company Commercialization Time
- 3.7 Market Competitive Analysis
 - 3.7.1 Global Generic Drugs Market CR5 and HHI
 - 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
 - 3.7.3 2023 Generic Drugs Tier 1, Tier 2, and Tier
- 3.8 Mergers & Acquisitions, Expansion

4 GENERIC DRUGS MARKET BY TYPE

- 4.1 Generic Drugs Type Introduction
 - 4.1.1 Prescription
 - 4.1.2 Non-Prescription Drugs
- 4.2 Global Generic Drugs Sales Value by Type
- 4.2.1 Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030)
- 4.2.2 Global Generic Drugs Sales Value by Type (2019-2030)



4.2.3 Global Generic Drugs Sales Value Share by Type (2019-2030)

5 GENERIC DRUGS MARKET BY APPLICATION

- 5.1 Generic Drugs Application Introduction
 - 5.1.1 Hospital
 - 5.1.2 Clinic
 - 5.1.3 Others
- 5.2 Global Generic Drugs Sales Value by Application
 - 5.2.1 Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030)
 - 5.2.2 Global Generic Drugs Sales Value by Application (2019-2030)
 - 5.2.3 Global Generic Drugs Sales Value Share by Application (2019-2030)

6 GENERIC DRUGS MARKET BY REGION

- 6.1 Global Generic Drugs Sales Value by Region: 2019 VS 2023 VS 2030
- 6.2 Global Generic Drugs Sales Value by Region (2019-2030)
 - 6.2.1 Global Generic Drugs Sales Value by Region: 2019-2024
 - 6.2.2 Global Generic Drugs Sales Value by Region (2025-2030)
- 6.3 North America
 - 6.3.1 North America Generic Drugs Sales Value (2019-2030)
 - 6.3.2 North America Generic Drugs Sales Value Share by Country, 2023 VS 2030
- 6.4 Europe
 - 6.4.1 Europe Generic Drugs Sales Value (2019-2030)
 - 6.4.2 Europe Generic Drugs Sales Value Share by Country, 2023 VS 2030
- 6.5 Asia-Pacific
 - 6.5.1 Asia-Pacific Generic Drugs Sales Value (2019-2030)
 - 6.5.2 Asia-Pacific Generic Drugs Sales Value Share by Country, 2023 VS 2030
- 6.6 Latin America
 - 6.6.1 Latin America Generic Drugs Sales Value (2019-2030)
- 6.6.2 Latin America Generic Drugs Sales Value Share by Country, 2023 VS 2030
- 6.7 Middle East & Africa
 - 6.7.1 Middle East & Africa Generic Drugs Sales Value (2019-2030)
- 6.7.2 Middle East & Africa Generic Drugs Sales Value Share by Country, 2023 VS 2030

7 GENERIC DRUGS MARKET BY COUNTRY

7.1 Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030



- 7.2 Global Generic Drugs Sales Value by Country (2019-2030)
 - 7.2.1 Global Generic Drugs Sales Value by Country (2019-2024)
- 7.2.2 Global Generic Drugs Sales Value by Country (2025-2030)

7.3 USA

- 7.3.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.3.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.3.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.4 Canada

- 7.4.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.4.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.4.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.5 Germany

- 7.5.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.5.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.5.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.6 France

- 7.6.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.6.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.6.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030 7.7 U.K.
 - 7.7.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.7.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.7.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 20307.8 Italy

7.8.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)

- 7.8.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.8.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.9 Netherlands

- 7.9.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.9.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.9.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.10 Nordic Countries

- 7.10.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.10.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.10.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.11 China

- 7.11.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.11.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.11.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030



7.12 Japan

- 7.12.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.12.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.12.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.13 South Korea

- 7.13.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.13.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.13.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.14 Southeast Asia

- 7.14.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.14.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.14.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.15 India

- 7.15.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.15.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.15.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.16 Australia

- 7.16.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.16.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.16.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.17 Mexico

- 7.17.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.17.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.17.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.18 Brazil

- 7.18.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.18.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.18.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.19 Turkey

- 7.19.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.19.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.19.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.20 Saudi Arabia

- 7.20.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.20.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
- 7.20.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

7.21 UAE

- 7.21.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
- 7.21.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030



7.21.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030

8 COMPANY PROFILES

Ω	1	Tava
$^{\circ}$	- 1	1672

- 8.1.1 Teva Comapny Information
- 8.1.2 Teva Business Overview
- 8.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
- 8.1.4 Teva Generic Drugs Product Portfolio
- 8.1.5 Teva Recent Developments
- 8.2 Novartis Sandoz
 - 8.2.1 Novartis Sandoz Comapny Information
 - 8.2.2 Novartis Sandoz Business Overview
 - 8.2.3 Novartis Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.2.4 Novartis Sandoz Generic Drugs Product Portfolio
 - 8.2.5 Novartis Sandoz Recent Developments
- 8.3 Mylan
 - 8.3.1 Mylan Comapny Information
 - 8.3.2 Mylan Business Overview
 - 8.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.3.4 Mylan Generic Drugs Product Portfolio
 - 8.3.5 Mylan Recent Developments
- 8.4 Sun Pharmaceutical
 - 8.4.1 Sun Pharmaceutical Comapny Information
 - 8.4.2 Sun Pharmaceutical Business Overview
 - 8.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
 - 8.4.5 Sun Pharmaceutical Recent Developments
- 8.5 Aspen
 - 8.5.1 Aspen Comapny Information
 - 8.5.2 Aspen Business Overview
 - 8.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.5.4 Aspen Generic Drugs Product Portfolio
 - 8.5.5 Aspen Recent Developments
- 8.6 Fresenius Kabi
 - 8.6.1 Fresenius Kabi Comapny Information
 - 8.6.2 Fresenius Kabi Business Overview
 - 8.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.6.4 Fresenius Kabi Generic Drugs Product Portfolio



8.6.5 Fresenius Kabi Recent Developments

- 8.7 Pfizer (Hospira)
 - 8.7.1 Pfizer (Hospira) Comapny Information
 - 8.7.2 Pfizer (Hospira) Business Overview
 - 8.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
 - 8.7.5 Pfizer (Hospira) Recent Developments
- 8.8 Sanofi
 - 8.8.1 Sanofi Comapny Information
 - 8.8.2 Sanofi Business Overview
 - 8.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.8.4 Sanofi Generic Drugs Product Portfolio
 - 8.8.5 Sanofi Recent Developments
- 8.9 Aurobindo
 - 8.9.1 Aurobindo Comapny Information
 - 8.9.2 Aurobindo Business Overview
 - 8.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.9.4 Aurobindo Generic Drugs Product Portfolio
 - 8.9.5 Aurobindo Recent Developments
- 8.10 Lupin
 - 8.10.1 Lupin Comapny Information
 - 8.10.2 Lupin Business Overview
 - 8.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.10.4 Lupin Generic Drugs Product Portfolio
 - 8.10.5 Lupin Recent Developments
- 8.11 Dr. Reddy's
 - 8.11.1 Dr. Reddy's Comapny Information
 - 8.11.2 Dr. Reddy's Business Overview
 - 8.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.11.4 Dr. Reddy's Generic Drugs Product Portfolio
 - 8.11.5 Dr. Reddy's Recent Developments
- 8.12 Apotex
 - 8.12.1 Apotex Comapny Information
 - 8.12.2 Apotex Business Overview
 - 8.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.12.4 Apotex Generic Drugs Product Portfolio
 - 8.12.5 Apotex Recent Developments
- 8.13 Cipla
- 8.13.1 Cipla Comapny Information



- 8.13.2 Cipla Business Overview
- 8.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
- 8.13.4 Cipla Generic Drugs Product Portfolio
- 8.13.5 Cipla Recent Developments
- 8.14 ENDO (Par Pharmaceutical)
 - 8.14.1 ENDO (Par Pharmaceutical) Comapny Information
 - 8.14.2 ENDO (Par Pharmaceutical) Business Overview
- 8.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
- 8.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
- 8.14.5 ENDO (Par Pharmaceutical) Recent Developments
- 8.15 Stada Arzneimittel
 - 8.15.1 Stada Arzneimittel Comapny Information
 - 8.15.2 Stada Arzneimittel Business Overview
 - 8.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
 - 8.15.5 Stada Arzneimittel Recent Developments
- 8.16 Krka Group
 - 8.16.1 Krka Group Comapny Information
 - 8.16.2 Krka Group Business Overview
 - 8.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.16.4 Krka Group Generic Drugs Product Portfolio
 - 8.16.5 Krka Group Recent Developments
- 8.17 Nichi-Iko Pharmaceutical
 - 8.17.1 Nichi-Iko Pharmaceutical Comapny Information
 - 8.17.2 Nichi-Iko Pharmaceutical Business Overview
- 8.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
 - 8.17.5 Nichi-Iko Pharmaceutical Recent Developments
- 8.18 Valeant
 - 8.18.1 Valeant Comapny Information
 - 8.18.2 Valeant Business Overview
 - 8.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.18.4 Valeant Generic Drugs Product Portfolio
 - 8.18.5 Valeant Recent Developments
- 8.19 Zydus Cadila
 - 8.19.1 Zydus Cadila Comapny Information
 - 8.19.2 Zydus Cadila Business Overview



- 8.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
- 8.19.4 Zydus Cadila Generic Drugs Product Portfolio
- 8.19.5 Zydus Cadila Recent Developments
- 8.20 Hikma
 - 8.20.1 Hikma Comapny Information
 - 8.20.2 Hikma Business Overview
 - 8.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.20.4 Hikma Generic Drugs Product Portfolio
- 8.20.5 Hikma Recent Developments
- 8.21 Pharmaniaga Berhad
 - 8.21.1 Pharmaniaga Berhad Comapny Information
 - 8.21.2 Pharmaniaga Berhad Business Overview
 - 8.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
 - 8.21.5 Pharmaniaga Berhad Recent Developments
- 8.22 Hovid Berhad
 - 8.22.1 Hovid Berhad Comapny Information
 - 8.22.2 Hovid Berhad Business Overview
 - 8.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.22.4 Hovid Berhad Generic Drugs Product Portfolio
 - 8.22.5 Hovid Berhad Recent Developments
- 8.23 Duopharma Biotech
 - 8.23.1 Duopharma Biotech Comapny Information
 - 8.23.2 Duopharma Biotech Business Overview
 - 8.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.23.4 Duopharma Biotech Generic Drugs Product Portfolio
 - 8.23.5 Duopharma Biotech Recent Developments
- 8.24 Kotra Pharma
 - 8.24.1 Kotra Pharma Comapny Information
 - 8.24.2 Kotra Pharma Business Overview
 - 8.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.24.4 Kotra Pharma Generic Drugs Product Portfolio
 - 8.24.5 Kotra Pharma Recent Developments
- 8.25 HOE Pharmaceutical
 - 8.25.1 HOE Pharmaceutical Comapny Information
 - 8.25.2 HOE Pharmaceutical Business Overview
 - 8.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
 - 8.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
 - 8.25.5 HOE Pharmaceutical Recent Developments



8.26 Y.S.P. Industries

- 8.26.1 Y.S.P. Industries Comapny Information
- 8.26.2 Y.S.P. Industries Business Overview
- 8.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)
- 8.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
- 8.26.5 Y.S.P. Industries Recent Developments

9 CONCLUDING INSIGHTS

10 APPENDIX

- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
 - 10.5.1 Secondary Sources
 - 10.5.2 Primary Sources



List Of Tables

LIST OF TABLES

- Table 1. Generic Drugs Industry Trends
- Table 2. Generic Drugs Industry Drivers
- Table 3. Generic Drugs Industry Opportunities and Challenges
- Table 4. Generic Drugs Industry Restraints
- Table 5. Global Generic Drugs Revenue by Company (US\$ Million) & (2019-2024)
- Table 6. Global Generic Drugs Revenue Share by Company (2019-2024)
- Table 7. Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024 & (US\$ Million)
- Table 8. Global Generic Drugs Key Company Manufacturing Base & Headquarters
- Table 9. Global Generic Drugs Company, Product Type & Application
- Table 10. Global Generic Drugs Company Commercialization Time
- Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
- Table 12. Global Generic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
- Table 13. Mergers & Acquisitions, Expansion
- Table 14. Major Companies of Prescription
- Table 15. Major Companies of Non-Prescription Drugs
- Table 16. Global Generic Drugs Sales Value by Type 2019 VS 2023 VS 2030 (US\$ Million)
- Table 17. Global Generic Drugs Sales Value by Type (2019-2024) & (US\$ Million)
- Table 18. Global Generic Drugs Sales Value by Type (2025-2030) & (US\$ Million)
- Table 19. Global Generic Drugs Sales Value Share by Type (2019-2024)
- Table 20. Global Generic Drugs Sales Value Share by Type (2025-2030)
- Table 21. Major Companies of Hospital
- Table 22. Major Companies of Clinic
- Table 23. Major Companies of Others
- Table 24. Global Generic Drugs Sales Value by Application 2019 VS 2023 VS 2030 (US\$ Million)
- Table 25. Global Generic Drugs Sales Value by Application (2019-2024) & (US\$ Million)
- Table 26. Global Generic Drugs Sales Value by Application (2025-2030) & (US\$ Million)
- Table 27. Global Generic Drugs Sales Value Share by Application (2019-2024)
- Table 28. Global Generic Drugs Sales Value Share by Application (2025-2030)
- Table 29. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)
- Table 30. Global Generic Drugs Sales Value by Region (2019-2024) & (US\$ Million)



- Table 31. Global Generic Drugs Sales Value Share by Region (2019-2024)
- Table 32. Global Generic Drugs Sales Value by Region (2025-2030) & (US\$ Million)
- Table 33. Global Generic Drugs Sales Value Share by Region (2025-2030)
- Table 34. Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030 (US\$ Million)
- Table 35. Global Generic Drugs Sales Value by Country (2019-2024) & (US\$ Million)
- Table 36. Global Generic Drugs Sales Value Market Share by Country (2019-2024)
- Table 37. Global Generic Drugs Sales Value by Country (2025-2030) & (US\$ Million)
- Table 38. Global Generic Drugs Sales Value Market Share by Country (2025-2030)
- Table 39. Teva Company Information
- Table 40. Teva Business Overview
- Table 41. Teva Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 42. Teva Generic Drugs Product Portfolio
- Table 43. Teva Recent Development
- Table 44. Novartis Sandoz Company Information
- Table 45. Novartis Sandoz Business Overview
- Table 46. Novartis Sandoz Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 47. Novartis Sandoz Generic Drugs Product Portfolio
- Table 48. Novartis Sandoz Recent Development
- Table 49. Mylan Company Information
- Table 50. Mylan Business Overview
- Table 51. Mylan Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 52. Mylan Generic Drugs Product Portfolio
- Table 53. Mylan Recent Development
- Table 54. Sun Pharmaceutical Company Information
- Table 55. Sun Pharmaceutical Business Overview
- Table 56. Sun Pharmaceutical Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 57. Sun Pharmaceutical Generic Drugs Product Portfolio
- Table 58. Sun Pharmaceutical Recent Development
- Table 59. Aspen Company Information
- Table 60. Aspen Business Overview
- Table 61. Aspen Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)
- Table 62. Aspen Generic Drugs Product Portfolio
- Table 63. Aspen Recent Development
- Table 64. Fresenius Kabi Company Information
- Table 65. Fresenius Kabi Business Overview
- Table 66. Fresenius Kabi Generic Drugs Revenue (US\$ Million) and Gross Margin



(2019-2024)

Table 67. Fresenius Kabi Generic Drugs Product Portfolio

Table 68. Fresenius Kabi Recent Development

Table 69. Pfizer (Hospira) Company Information

Table 70. Pfizer (Hospira) Business Overview

Table 71. Pfizer (Hospira) Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 72. Pfizer (Hospira) Generic Drugs Product Portfolio

Table 73. Pfizer (Hospira) Recent Development

Table 74. Sanofi Company Information

Table 75. Sanofi Business Overview

Table 76. Sanofi Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 77. Sanofi Generic Drugs Product Portfolio

Table 78. Sanofi Recent Development

Table 79. Aurobindo Company Information

Table 80. Aurobindo Business Overview

Table 81. Aurobindo Generic Drugs Revenue (US\$ Million) and Gross Margin

(2019-2024)

Table 82. Aurobindo Generic Drugs Product Portfolio

Table 83. Aurobindo Recent Development

Table 84. Lupin Company Information

Table 85. Lupin Business Overview

Table 86. Lupin Generic Drugs Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 87. Lupin Generic Drugs Product Portfolio

Table 88. Lupin Recent Development

Table 89. Dr. Reddy's Company Information

Table 90. Dr. Reddy's Business Overview

Table 91. Dr. Reddy's Generic Drugs Sales (K MT), Value (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 92. Dr. Reddy's Generic Drugs Product Portfolio

Table 93. Dr. Reddy's Recent Development

Table 94. Apotex Company Information

Table 95. Apotex Business Overview

Table 96. Apotex Generic Drugs Sales (K MT), Value (US\$ Million), Price (USD/MT)

and Gross Margin (2019-2024)

Table 97. Apotex Generic Drugs Product Portfolio

Table 98. Apotex Recent Development

Table 99. Cipla Company Information

Table 100. Cipla Business Overview



Table 101. Cipla Generic Drugs Sales (K MT), Value (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 102. Cipla Generic Drugs Product Portfolio

Table 103. Cipla Recent Development

Table 104. ENDO (Par Pharmaceutical) Company Information

Table 105. ENDO (Par Pharmaceutical) Business Overview

Table 106. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Value (US\$

Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio

Table 108. ENDO (Par Pharmaceutical) Recent Development

Table 109. Stada Arzneimittel Company Information

Table 110. Stada Arzneimittel Business Overview

Table 111. Stada Arzneimittel Generic Drugs Sales (K MT), Value (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 112. Stada Arzneimittel Generic Drugs Product Portfolio

Table 113. Stada Arzneimittel Recent Development

Table 114. Krka Group Company Information

Table 115. Krka Group Business Overview

Table 116. Krka Group Generic Drugs Sales (K MT), Value (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 117. Krka Group Generic Drugs Product Portfolio

Table 118. Krka Group Recent Development

Table 119. Nichi-Iko Pharmaceutical Company Information

Table 120. Nichi-lko Pharmaceutical Business Overview

Table 121. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Value (US\$ Million),

Price (USD/MT) and Gross Margin (2019-2024)

Table 122. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio

Table 123. Nichi-Iko Pharmaceutical Recent Development

Table 124. Valeant Company Information

Table 125. Valeant Business Overview

Table 126. Valeant Generic Drugs Sales (K MT), Value (US\$ Million), Price (USD/MT)

and Gross Margin (2019-2024)

Table 127. Valeant Generic Drugs Product Portfolio

Table 128. Valeant Recent Development

Table 129. Zydus Cadila Company Information

Table 130. Zydus Cadila Business Overview

Table 131. Zydus Cadila Generic Drugs Sales (K MT), Value (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 132. Zydus Cadila Generic Drugs Product Portfolio



- Table 133. Zydus Cadila Recent Development
- Table 134. Hikma Company Information
- Table 135. Hikma Business Overview
- Table 136. Hikma Generic Drugs Sales (K MT), Value (US\$ Million), Price (USD/MT)
- and Gross Margin (2019-2024)
- Table 137. Hikma Generic Drugs Product Portfolio
- Table 138. Hikma Recent Development
- Table 139. Pharmaniaga Berhad Company Information
- Table 140. Pharmaniaga Berhad Business Overview
- Table 141. Pharmaniaga Berhad Generic Drugs Sales (K MT), Value (US\$ Million),
- Price (USD/MT) and Gross Margin (2019-2024)
- Table 142. Pharmaniaga Berhad Generic Drugs Product Portfolio
- Table 143. Pharmaniaga Berhad Recent Development
- Table 144. Hovid Berhad Company Information
- Table 145. Hovid Berhad Business Overview
- Table 146. Hovid Berhad Generic Drugs Sales (K MT), Value (US\$ Million), Price
- (USD/MT) and Gross Margin (2019-2024)
- Table 147. Hovid Berhad Generic Drugs Product Portfolio
- Table 148. Hovid Berhad Recent Development
- Table 149. Duopharma Biotech Company Information
- Table 150. Duopharma Biotech Business Overview
- Table 151. Duopharma Biotech Generic Drugs Sales (K MT), Value (US\$ Million), Price
- (USD/MT) and Gross Margin (2019-2024)
- Table 152. Duopharma Biotech Generic Drugs Product Portfolio
- Table 153. Duopharma Biotech Recent Development
- Table 154. Kotra Pharma Company Information
- Table 155. Kotra Pharma Business Overview
- Table 156. Kotra Pharma Generic Drugs Sales (K MT), Value (US\$ Million), Price
- (USD/MT) and Gross Margin (2019-2024)
- Table 157. Kotra Pharma Generic Drugs Product Portfolio
- Table 158. Kotra Pharma Recent Development
- Table 159. HOE Pharmaceutical Company Information
- Table 160. HOE Pharmaceutical Business Overview
- Table 161. HOE Pharmaceutical Generic Drugs Sales (K MT), Value (US\$ Million),
- Price (USD/MT) and Gross Margin (2019-2024)
- Table 162. HOE Pharmaceutical Generic Drugs Product Portfolio
- Table 163. HOE Pharmaceutical Recent Development
- Table 164. Y.S.P. Industries Company Information
- Table 165. Y.S.P. Industries Business Overview



Table 166. Y.S.P. Industries Generic Drugs Sales (K MT), Value (US\$ Million), Price

(USD/MT) and Gross Margin (2019-2024)

Table 167. Y.S.P. Industries Generic Drugs Product Portfolio

Table 168. Y.S.P. Industries Recent Development

Table 169. Research Programs/Design for This Report

Table 170. Authors List of This Report

Table 171. Secondary Sources

Table 172. Primary Sources



List Of Figures

LIST OF FIGURES

- Figure 1. Generic Drugs Product Picture
- Figure 2. Global Generic Drugs Market Size (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global Generic Drugs Market Size (2019-2030) & (US\$ Million)
- Figure 4. Global Generic Drugs Company Revenue Ranking in 2023 (US\$ Million)
- Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US\$ Million)
- Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
- Figure 7. Prescription Picture
- Figure 8. Non-Prescription Drugs Picture
- Figure 9. Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 10. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
- Figure 11. Global Generic Drugs Sales Value Share by Type (2019-2030)
- Figure 12. Hospital Picture
- Figure 13. Clinic Picture
- Figure 14. Others Picture
- Figure 15. Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US\$ Million)
- Figure 16. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
- Figure 17. Global Generic Drugs Sales Value Share by Application (2019-2030)
- Figure 18. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)
- Figure 19. Global Generic Drugs Sales Value Share by Region: 2019 VS 2023 VS 2030
- Figure 20. North America Generic Drugs Sales Value (2019-2030) & (US\$ Million)
- Figure 21. North America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
- Figure 22. Europe Generic Drugs Sales Value (2019-2030) & (US\$ Million)
- Figure 23. Europe Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
- Figure 24. Asia-Pacific Generic Drugs Sales Value (2019-2030) & (US\$ Million)
- Figure 25. Asia-Pacific Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
- Figure 26. Latin America Generic Drugs Sales Value (2019-2030) & (US\$ Million)
- Figure 27. Latin America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
- Figure 28. Middle East & Africa Generic Drugs Sales Value (2019-2030) & (US\$ Million)



- Figure 29. Middle East & Africa Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
- Figure 30. USA Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 31. USA Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 32. USA Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 33. Canada Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 34. Canada Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 35. Canada Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 36. Germany Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 37. Germany Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 38. Germany Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 39. France Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 40. France Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 41. France Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 42. U.K. Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 43. U.K. Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 44. U.K. Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 45. Italy Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 46. Italy Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 47. Italy Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 48. Netherlands Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 49. Netherlands Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 50. Netherlands Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 51. Nordic Countries Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 52. Nordic Countries Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 53. Nordic Countries Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
- Figure 54. China Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)
- Figure 55. China Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
- Figure 56. China Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)



Figure 57. Japan Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 58. Japan Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 59. Japan Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 60. South Korea Generic Drugs Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 61. South Korea Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 62. South Korea Generic Drugs Sales Valu



I would like to order

Product name: Global Generic Drugs Market Size, Manufacturers, Growth Analysis Industry Forecast to

2030

Product link: https://marketpublishers.com/r/GF8643CE028AEN.html

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GF8643CE028AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



